← SynDRA
DACLATASVIR
SynDRA canonical compound SYN0029157 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Mechanism of action | HCV inhibitor |
|---|
| Indication | hepatitis C |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- HCV inhibitor
- HCV NS5A INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- CYP3A4
- OPRK1
- NPY1R
- HRH1
- HRH2
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- MAOA
- MC3R
- MLNR
- NR1I2
- GHSR
- NR3C1
- OPRD1
- OPRM1
- PDE3A
- PDE4D
- PGR
- PTGS2
- SCN5A
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- HDAC6
- ESR1
- ADORA1
- CACNA1C
- ADORA2A
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- P-Glycoprotein Inhibitors
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Hepatitis C Virus NS5A Inhibitor
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- DAKLINZA
- daclatasvir dihydrochloride
- daclatasvir hydrochloride
- daklinza
- BMS-790052-05
- BMS-790052
- daclatasvir HCl
- daclatasivr
- EBP-883
- Daclatasvir (BMS-790052)
- CHEBI:82977
- C40H50N8O6
- Daclatasvir (USAN)
- cc-39
- Daclatasvir BMS 790052
- MLS006011140
- SCHEMBL2756027
- CHEMBL2023898
- SCHEMBL17897804
- KS-00000XPC
- EX-A410
- BMS 790052
- Daklinza
- BMS790052
- Daclatasvir [USAN]
- Daclatasvir dihydrochloride
- LI2427F9CI
- DACLATASVIR [MI]
- DACLATASVIR [INN]
- DACLATASVIR [WHO-DD]
- EBP883
- GTPL11266
- DTXSID901026404
- AMY36655
- BDBM50387084
- MFCD17129086
- s1482
- ZINC68204830
Look up DACLATASVIR in the interactive SynDRA portal →